AG˹ٷ

STOCK TITAN

[Form 4] New Jersey Resources Corp Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

The filing is a Form 144 notice, indicating that a holder intends to sell American Depositary Shares (ADS) of the issuer identified in the header as “BeOne Medicines Ltd.�.

  • Securities to be sold: 3,174 ADS
  • Estimated market value: $830,359.98
  • Planned sale date: 06/23/2025 on the NASDAQ
  • Broker: Morgan Stanley Smith Barney LLC, Executive Financial Services, New York

The seller, John Oyler, has also disposed of 10,267 ADS during the past three months in three separate transactions, generating aggregate gross proceeds of approximately $2.65 million.

The new sale, together with recent transactions, suggests continued insider liquidation. Relationship to the issuer is not disclosed in the form, and the filer affirms no undisclosed adverse information. No additional financial statements or operational details are provided in this notice.

La comunicazione è un avviso Formulario 144, che indica l'intenzione di un detentore di vendere American Depositary Shares (ADS) dell'emittente identificato nell'intestazione come “BeOne Medicines Ltd.�.

  • Titoli da vendere: 3.174 ADS
  • Valore di mercato stimato: 830.359,98 $
  • Data prevista per la vendita: 23/06/2025 sul NASDAQ
  • Intermediario: Morgan Stanley Smith Barney LLC, Executive Financial Services, New York

Il venditore, John Oyler, ha anche ceduto 10.267 ADS negli ultimi tre mesi in tre transazioni separate, generando proventi lordi complessivi di circa 2,65 milioni di $.

La nuova vendita, insieme alle transazioni recenti, suggerisce una continua liquidazione da parte di un insider. Il rapporto con l'emittente non è dichiarato nel modulo, e il dichiarante afferma l'assenza di informazioni negative non divulgate. Nessun ulteriore bilancio o dettaglio operativo è fornito in questo avviso.

La presentación es un aviso del Formulario 144, que indica que un titular tiene la intención de vender American Depositary Shares (ADS) del emisor identificado en el encabezado como “BeOne Medicines Ltd.�.

  • Valores a vender: 3.174 ADS
  • Valor estimado de mercado: 830.359,98 $
  • Fecha planeada de venta: 23/06/2025 en el NASDAQ
  • Corredor: Morgan Stanley Smith Barney LLC, Executive Financial Services, Nueva York

El vendedor, John Oyler, también ha vendido 10.267 ADS durante los últimos tres meses en tres transacciones separadas, generando ingresos brutos totales de aproximadamente 2,65 millones de $.

La nueva venta, junto con las transacciones recientes, sugiere una continua liquidación interna. La relación con el emisor no se revela en el formulario, y el declarante afirma que no hay información adversa no divulgada. No se proporcionan estados financieros adicionales ni detalles operativos en este aviso.

� 제출서는 � 144 통지��, 보유자가 헤더� “BeOne Medicines Ltd.”로 명시� 발행자의 미국 예탁 증서(ADS)� 판매� 의도� 나타냅니�.

  • 판매� 증권: 3,174 ADS
  • 추정 시장 가�: $830,359.98
  • 예정 판매�: 2025� 6� 23�, NASDAQ에서
  • 중개�: Morgan Stanley Smith Barney LLC, Executive Financial Services, 뉴욕

판매� John Oyler� 지� 3개월 동안 � 차례� 걸쳐 10,267 ADS� 처분하여 � � 265� 달러� 총수익을 올렸습니�.

이번 신규 판매와 최근 거래들을 종합� � � 내부자의 지속적� 매도 행위가 엿보입니�. 발행자와� 관계는 양식� 공개되어 있지 않으�, 제출자는 공개되지 않은 부정적 정보가 없음� 확인합니�. � 통지서에� 추가 재무제표� 운영 세부사항� 제공되지 않습니다.

Le dépôt est un avis Formulaire 144, indiquant qu’un détenteur a l’intention de vendre des American Depositary Shares (ADS) de l’émetteur identifié en en-tête comme « BeOne Medicines Ltd. ».

  • Titres à vendre : 3 174 ADS
  • Valeur marchande estimée : 830 359,98 $
  • Date prévue de la vente : 23/06/2025 sur le NASDAQ
  • Intermédiaire : Morgan Stanley Smith Barney LLC, Executive Financial Services, New York

Le vendeur, John Oyler, a également cédé 10 267 ADS au cours des trois derniers mois lors de trois transactions distinctes, générant un produit brut total d’environ 2,65 millions de $.

La nouvelle vente, combinée aux transactions récentes, suggère une liquidation continue de la part d’un initié. La relation avec l’émetteur n’est pas divulguée dans le formulaire, et le déclarant affirme qu’aucune information défavorable non divulguée n’existe. Aucun état financier supplémentaire ni détail opérationnel n’est fourni dans cet avis.

Die Einreichung ist eine Formular 144-Mitteilung, die anzeigt, dass ein Inhaber beabsichtigt, American Depositary Shares (ADS) des im Kopf als „BeOne Medicines Ltd.� bezeichneten Emittenten zu verkaufen.

  • Zu verkaufende Wertpapiere: 3.174 ADS
  • Geschätzter Marktwert: 830.359,98 $
  • Geplanter Verkaufstermin: 23.06.2025 an der NASDAQ
  • Broker: Morgan Stanley Smith Barney LLC, Executive Financial Services, New York

Der Verkäufer, John Oyler, hat in den letzten drei Monaten außerdem 10.267 ADS in drei separaten Transaktionen veräußert und dabei Bruttoerlöse von etwa 2,65 Millionen $ erzielt.

Der neue Verkauf zusammen mit den jüngsten Transaktionen deutet auf eine fortgesetzte Insider-Veräußerung hin. Die Beziehung zum Emittenten wird im Formular nicht offengelegt, und der Einreicher bestätigt, dass keine nicht offengelegten negativen Informationen vorliegen. In dieser Mitteilung werden keine zusätzlichen Finanzberichte oder operative Details bereitgestellt.

Positive
  • None.
Negative
  • Continued insider selling: 3,174 ADS planned plus 10,267 ADS recently sold may signal reduced insider confidence.
  • Market supply impact: Additional shares entering the market could exert modest downward pressure on the stock.

Insights

TL;DR � Insider plans to sell another 3,174 ADS after ~$2.6 M prior sales; signal skews negative.

Form 144 filings announce intended insider sales. Here, John Oyler plans to divest 3,174 ADS (~$0.83 M) on 06/23/25. He already sold 10,267 ADS in the last 90 days, indicating a steady reduction of holdings. While sellers attest to possessing no undisclosed adverse information, repeated dispositions often pressure sentiment, especially absent offsetting insider buys. Without operational data, the filing’s sole material element is continued insider selling, which investors typically read as mildly bearish.

La comunicazione è un avviso Formulario 144, che indica l'intenzione di un detentore di vendere American Depositary Shares (ADS) dell'emittente identificato nell'intestazione come “BeOne Medicines Ltd.�.

  • Titoli da vendere: 3.174 ADS
  • Valore di mercato stimato: 830.359,98 $
  • Data prevista per la vendita: 23/06/2025 sul NASDAQ
  • Intermediario: Morgan Stanley Smith Barney LLC, Executive Financial Services, New York

Il venditore, John Oyler, ha anche ceduto 10.267 ADS negli ultimi tre mesi in tre transazioni separate, generando proventi lordi complessivi di circa 2,65 milioni di $.

La nuova vendita, insieme alle transazioni recenti, suggerisce una continua liquidazione da parte di un insider. Il rapporto con l'emittente non è dichiarato nel modulo, e il dichiarante afferma l'assenza di informazioni negative non divulgate. Nessun ulteriore bilancio o dettaglio operativo è fornito in questo avviso.

La presentación es un aviso del Formulario 144, que indica que un titular tiene la intención de vender American Depositary Shares (ADS) del emisor identificado en el encabezado como “BeOne Medicines Ltd.�.

  • Valores a vender: 3.174 ADS
  • Valor estimado de mercado: 830.359,98 $
  • Fecha planeada de venta: 23/06/2025 en el NASDAQ
  • Corredor: Morgan Stanley Smith Barney LLC, Executive Financial Services, Nueva York

El vendedor, John Oyler, también ha vendido 10.267 ADS durante los últimos tres meses en tres transacciones separadas, generando ingresos brutos totales de aproximadamente 2,65 millones de $.

La nueva venta, junto con las transacciones recientes, sugiere una continua liquidación interna. La relación con el emisor no se revela en el formulario, y el declarante afirma que no hay información adversa no divulgada. No se proporcionan estados financieros adicionales ni detalles operativos en este aviso.

� 제출서는 � 144 통지��, 보유자가 헤더� “BeOne Medicines Ltd.”로 명시� 발행자의 미국 예탁 증서(ADS)� 판매� 의도� 나타냅니�.

  • 판매� 증권: 3,174 ADS
  • 추정 시장 가�: $830,359.98
  • 예정 판매�: 2025� 6� 23�, NASDAQ에서
  • 중개�: Morgan Stanley Smith Barney LLC, Executive Financial Services, 뉴욕

판매� John Oyler� 지� 3개월 동안 � 차례� 걸쳐 10,267 ADS� 처분하여 � � 265� 달러� 총수익을 올렸습니�.

이번 신규 판매와 최근 거래들을 종합� � � 내부자의 지속적� 매도 행위가 엿보입니�. 발행자와� 관계는 양식� 공개되어 있지 않으�, 제출자는 공개되지 않은 부정적 정보가 없음� 확인합니�. � 통지서에� 추가 재무제표� 운영 세부사항� 제공되지 않습니다.

Le dépôt est un avis Formulaire 144, indiquant qu’un détenteur a l’intention de vendre des American Depositary Shares (ADS) de l’émetteur identifié en en-tête comme « BeOne Medicines Ltd. ».

  • Titres à vendre : 3 174 ADS
  • Valeur marchande estimée : 830 359,98 $
  • Date prévue de la vente : 23/06/2025 sur le NASDAQ
  • Intermédiaire : Morgan Stanley Smith Barney LLC, Executive Financial Services, New York

Le vendeur, John Oyler, a également cédé 10 267 ADS au cours des trois derniers mois lors de trois transactions distinctes, générant un produit brut total d’environ 2,65 millions de $.

La nouvelle vente, combinée aux transactions récentes, suggère une liquidation continue de la part d’un initié. La relation avec l’émetteur n’est pas divulguée dans le formulaire, et le déclarant affirme qu’aucune information défavorable non divulguée n’existe. Aucun état financier supplémentaire ni détail opérationnel n’est fourni dans cet avis.

Die Einreichung ist eine Formular 144-Mitteilung, die anzeigt, dass ein Inhaber beabsichtigt, American Depositary Shares (ADS) des im Kopf als „BeOne Medicines Ltd.� bezeichneten Emittenten zu verkaufen.

  • Zu verkaufende Wertpapiere: 3.174 ADS
  • Geschätzter Marktwert: 830.359,98 $
  • Geplanter Verkaufstermin: 23.06.2025 an der NASDAQ
  • Broker: Morgan Stanley Smith Barney LLC, Executive Financial Services, New York

Der Verkäufer, John Oyler, hat in den letzten drei Monaten außerdem 10.267 ADS in drei separaten Transaktionen veräußert und dabei Bruttoerlöse von etwa 2,65 Millionen $ erzielt.

Der neue Verkauf zusammen mit den jüngsten Transaktionen deutet auf eine fortgesetzte Insider-Veräußerung hin. Die Beziehung zum Emittenten wird im Formular nicht offengelegt, und der Einreicher bestätigt, dass keine nicht offengelegten negativen Informationen vorliegen. In dieser Mitteilung werden keine zusätzlichen Finanzberichte oder operative Details bereitgestellt.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Migliaccio Patrick J.

(Last) (First) (Middle)
1415 WYCKOFF ROAD

(Street)
WALL NJ 07719

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
NEW JERSEY RESOURCES CORP [ NJR ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Senior VP and COO, NJNG
3. Date of Earliest Transaction (Month/Day/Year)
06/18/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/18/2025 S 1,500 D $44.22 35,689.642(1) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Total adjusted upward by 65.991 shares to reflect the market-based change in the reporting person's balance in the New Jersey Resources Corporation Employees' Retirement Savings Plan, which is a plan qualified under Section 401(k) of the Internal Revenue Code of 1986, as amended.
Remarks:
/s/ Tejal K. Mehta, as attorney-in-fact for Patrick J. Migliaccio 06/23/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What number of BeOne Medicines (ONC) ADS are being sold under this Form 144?

3,174 ADS are slated for sale.

What is the approximate market value of the planned sale?

The filing lists an aggregate market value of $830,359.98 for the 3,174 ADS.

When is the proposed sale date for the ONC ADS?

The seller intends to execute the sale on 06/23/2025.

How many BeOne Medicines ADS has the filer sold in the prior three months?

The filer disposed of 10,267 ADS in three transactions between 06/06/25 and 06/17/25.

What is Form 144 and why is it important for investors?

Form 144 gives public notice of a proposed insider sale, allowing investors to track insider trading activity and gauge sentiment.

Which broker is handling the transaction?

Morgan Stanley Smith Barney LLC, Executive Financial Services is listed as the broker.
New Jersey Res

NYSE:NJR

NJR Rankings

NJR Latest News

NJR Latest SEC Filings

NJR Stock Data

4.59B
99.86M
0.45%
78.21%
2.65%
Utilities - Regulated Gas
Natural Gas Distribution
United States
WALL